In the BioHarmony Drug Report Database

"Preview" Icon

Setmelanotide

Imcivree (setmelanotide) is a protein pharmaceutical. Setmelanotide was first approved as Imcivree on 2020-11-25. It has been approved in Europe to treat obesity. It is known to target melanocortin receptor 4, melanocortin receptor 3, melanocyte-stimulating hormone receptor, and melanocortin receptor 5. Imcivree’s patent is valid until 2027-10-13 (FDA).

 

Trade Name

 

Imcivree
 

Common Name

 

setmelanotide
 

ChEMBL ID

 

CHEMBL3301624
 

Indication

 

obesity
 

Drug Class

 

Peptides: melanocortin receptor antagonists

Image (chem structure or protein)

Setmelanotide structure rendering